T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Melanoma|Meningioma|Breast Cancer|Non-Small Cell Lung Cancer|Hepatocellular Cancer
Interventions: BIOLOGICAL: Anti-NY ESO-1 mTCR PBL|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin
Sponsor: National Cancer Institute (NCI)